MX2024000329A - Compuestos bifuncionales que comprenden una molecula que contiene una porcion dirigida a la proteina smarca (ptm) enlazada a una porcion de una molecula de union de ligasa de ubiquitina e3 (ulm), y su uso como moduladores de la ubiquitinacion dirigidos al tratamiento del cancer. - Google Patents
Compuestos bifuncionales que comprenden una molecula que contiene una porcion dirigida a la proteina smarca (ptm) enlazada a una porcion de una molecula de union de ligasa de ubiquitina e3 (ulm), y su uso como moduladores de la ubiquitinacion dirigidos al tratamiento del cancer.Info
- Publication number
- MX2024000329A MX2024000329A MX2024000329A MX2024000329A MX2024000329A MX 2024000329 A MX2024000329 A MX 2024000329A MX 2024000329 A MX2024000329 A MX 2024000329A MX 2024000329 A MX2024000329 A MX 2024000329A MX 2024000329 A MX2024000329 A MX 2024000329A
- Authority
- MX
- Mexico
- Prior art keywords
- target protein
- present disclosure
- compounds
- brm
- associated methods
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 230000008685 targeting Effects 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 abstract 6
- 108090000623 proteins and genes Proteins 0.000 abstract 6
- 101000702559 Homo sapiens Probable global transcription activator SNF2L2 Proteins 0.000 abstract 2
- 102100031021 Probable global transcription activator SNF2L2 Human genes 0.000 abstract 2
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 abstract 2
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 abstract 2
- 230000001588 bifunctional effect Effects 0.000 abstract 2
- 230000015556 catabolic process Effects 0.000 abstract 2
- 238000006731 degradation reaction Methods 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000005764 inhibitory process Effects 0.000 abstract 2
- 238000009825 accumulation Methods 0.000 abstract 1
- 230000002776 aggregation Effects 0.000 abstract 1
- 238000004220 aggregation Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente descripción se refiere a compuestos bifuncionales, que son útiles como moduladores de SMARCA2 o BRM (proteína diana). En particular, la presente descripción se refiere a compuestos bifuncionales, que contienen en un extremo un ligando que se une a la ligasa de ubiquitina E3 de Von Hippel-Lindau, y en el otro extremo una porción que se une a la proteína diana, de manera que la proteína diana se coloca en la proximidad de la ligasa de ubiquitina para efectuar la degradación (e inhibición) de la proteína diana. La presente descripción exhibe un amplio intervalo de actividades farmacológicas asociadas con la degradación/inhibición de la proteína diana. Las enfermedades o trastornos que resultan de la agregación o acumulación de la proteína diana se tratan o se previenen con los compuestos y composiciones de la presente descripción.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862651186P | 2018-04-01 | 2018-04-01 | |
US201962797754P | 2019-01-28 | 2019-01-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2024000329A true MX2024000329A (es) | 2024-01-25 |
Family
ID=66175525
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020010368A MX2020010368A (es) | 2018-04-01 | 2019-04-01 | Compuestos dirigidos a brm y métodos de uso asociados. |
MX2024000329A MX2024000329A (es) | 2018-04-01 | 2020-10-01 | Compuestos bifuncionales que comprenden una molecula que contiene una porcion dirigida a la proteina smarca (ptm) enlazada a una porcion de una molecula de union de ligasa de ubiquitina e3 (ulm), y su uso como moduladores de la ubiquitinacion dirigidos al tratamiento del cancer. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020010368A MX2020010368A (es) | 2018-04-01 | 2019-04-01 | Compuestos dirigidos a brm y métodos de uso asociados. |
Country Status (17)
Country | Link |
---|---|
US (2) | US20190300521A1 (es) |
EP (1) | EP3774789A1 (es) |
JP (2) | JP2021520350A (es) |
KR (2) | KR20240130153A (es) |
CN (1) | CN112166114A (es) |
AU (3) | AU2019249849C1 (es) |
BR (1) | BR112020020196A2 (es) |
CA (1) | CA3094305A1 (es) |
CL (1) | CL2020002546A1 (es) |
CO (1) | CO2020013762A2 (es) |
CR (1) | CR20200527A (es) |
IL (1) | IL277677A (es) |
MX (2) | MX2020010368A (es) |
PE (1) | PE20212108A1 (es) |
PH (1) | PH12020500663A1 (es) |
SG (1) | SG11202008898UA (es) |
WO (1) | WO2019195201A1 (es) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11161841B2 (en) | 2018-04-04 | 2021-11-02 | Arvinas Operations, Inc. | Modulators of proteolysis and associated methods of use |
WO2019207538A1 (en) * | 2018-04-26 | 2019-10-31 | Aurigene Discovery Technologies Limited | Pyridazine derivatives as smarca2/4 degraders |
US11771697B2 (en) | 2018-04-30 | 2023-10-03 | Dana-Farber Cancer Institute, Inc. | Small molecule degraders of polybromo-1 (PBRM1) |
CN112912376A (zh) | 2018-08-20 | 2021-06-04 | 阿尔维纳斯运营股份有限公司 | 用于治疗神经变性疾病的具有E3泛素连接酶结合活性并靶向α-突触核蛋白的蛋白水解靶向嵌合(PROTAC)化合物 |
WO2020086858A1 (en) | 2018-10-24 | 2020-04-30 | Genentech, Inc. | Conjugated chemical inducers of degradation and methods of use |
WO2020132561A1 (en) | 2018-12-20 | 2020-06-25 | C4 Therapeutics, Inc. | Targeted protein degradation |
JP7548992B2 (ja) | 2019-07-17 | 2024-09-10 | アルビナス・オペレーションズ・インコーポレイテッド | タウタンパク質標的化化合物および関連する使用方法 |
JP7502425B2 (ja) * | 2019-10-01 | 2024-06-18 | アルヴィナス・オペレーションズ・インコーポレイテッド | Brm標的化化合物および関連使用方法 |
WO2021074414A1 (en) * | 2019-10-16 | 2021-04-22 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | Oxazole and thioazole-type cullin ring ubiquitin ligase compounds and uses thereof |
CN114599428A (zh) * | 2019-10-28 | 2022-06-07 | 豪夫迈·罗氏有限公司 | 双功能化合物 |
US20230024096A1 (en) * | 2019-10-29 | 2023-01-26 | Hoffmann-La Roche Inc. | Bifunctional compounds for the treatment of cancer |
CA3162502A1 (en) | 2019-12-23 | 2021-07-01 | Yi Zhang | Smarca degraders and uses thereof |
CA3166404A1 (en) * | 2020-01-29 | 2021-08-05 | Matthew Netherton | A bifunctional molecule comprising an active compound,a linker and a degradation moiety, and its use to treat disorders associated with baf complex function |
TW202140485A (zh) | 2020-01-29 | 2021-11-01 | 美商福宏治療公司 | 化合物及其用途 |
WO2021252666A1 (en) | 2020-06-09 | 2021-12-16 | Prelude Therapeutics, Incorporated | Brm targeting compounds and associated methods of use |
KR20230042032A (ko) | 2020-07-21 | 2023-03-27 | 제넨테크, 인크. | Brm 분해의 항체 접합 화학 유도제 및 이의 방법 |
US11787800B2 (en) | 2020-07-29 | 2023-10-17 | Foghorn Therapeutics Inc. | BRD9 degraders and uses thereof |
JP2023536504A (ja) * | 2020-08-04 | 2023-08-25 | オーリジーン オンコロジー リミテッド | Smarca2および/またはsmarca4分解剤としての6置換ピリダジン化合物 |
CN116745295A (zh) * | 2020-11-06 | 2023-09-12 | 普莱鲁德疗法有限公司 | Brm靶向化合物及相关使用方法 |
WO2022125804A1 (en) * | 2020-12-09 | 2022-06-16 | Kymera Therapeutics, Inc. | Smarca degraders and uses thereof |
AU2022207648A1 (en) | 2021-01-13 | 2023-07-27 | Monte Rosa Therapeutics Ag | Isoindolinone compounds |
TW202241855A (zh) * | 2021-01-27 | 2022-11-01 | 美商富曼西公司 | 用於防治無脊椎有害生物之唑類化合物 |
WO2022221673A1 (en) | 2021-04-16 | 2022-10-20 | Arvinas Operations, Inc. | Modulators of bcl6 proteolysis and associated methods of use |
EP4333899A1 (en) | 2021-05-05 | 2024-03-13 | Biogen MA Inc. | Compounds for targeting degradation of bruton's tyrosine kinase |
KR20240004983A (ko) * | 2021-05-10 | 2024-01-11 | 포그혼 쎄라퓨틱스 인크. | 화합물 및 이의 용도 |
US11767330B2 (en) | 2021-07-06 | 2023-09-26 | Foghorn Therapeutics Inc. | Citrate salt, pharmaceutical compositions, and methods of making and using the same |
WO2023283372A1 (en) | 2021-07-07 | 2023-01-12 | Biogen Ma Inc. | Compounds for targeting degradation of irak4 proteins |
CA3224732A1 (en) | 2021-07-07 | 2023-01-12 | Kevin M. Guckian | Compounds for targeting degradation of irak4 proteins |
WO2023287787A1 (en) | 2021-07-13 | 2023-01-19 | Prelude Therapeutics, Incorporated | Brm targeting compounds and associated methods of use |
WO2023093728A1 (zh) * | 2021-11-23 | 2023-06-01 | 江苏先声药业有限公司 | Brm选择性降解剂化合物及其应用 |
WO2023096987A1 (en) | 2021-11-24 | 2023-06-01 | Arvinas Operations, Inc. | Brm targeting compounds and associated methods of use |
CN118679160A (zh) | 2021-11-24 | 2024-09-20 | 阿维纳斯运营公司 | Brm靶向化合物和相关的使用方法 |
WO2023129506A1 (en) * | 2021-12-28 | 2023-07-06 | Board Of Regents, The University Of Texas System | Potent and selective smarca2 degrading chimeric molecules as cancer therapeutics |
AR128331A1 (es) | 2022-01-26 | 2024-04-17 | Genentech Inc | Inductores químicos de degradación conjugados con anticuerpos y métodos de estos |
AR128330A1 (es) | 2022-01-26 | 2024-04-17 | Genentech Inc | Inductores químicos de degradación conjugados con anticuerpo y métodos de estos |
WO2023245150A1 (en) | 2022-06-16 | 2023-12-21 | Prelude Therapeutics Incorporated | Kat6 targeting compounds with ubiquitin ligase binding moiety |
WO2024002375A1 (zh) * | 2022-06-30 | 2024-01-04 | 甘李药业股份有限公司 | 一种用作smarca2/4抑制剂的化合物及其应用 |
CN115353468B (zh) * | 2022-08-19 | 2023-06-30 | 安阳工学院 | 一种对甲苯磺酰氧基取代低聚乙二醇丙酸叔丁酯的制备方法 |
WO2024107711A1 (en) | 2022-11-15 | 2024-05-23 | Prelude Therapeutics Incorporated | Brm targeting compounds and associated methods of use |
WO2024179529A1 (zh) * | 2023-02-28 | 2024-09-06 | 上海海雁医药科技有限公司 | 取代的三环衍生物及其药物组合物和用途 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
CN117736134A (zh) * | 2012-01-12 | 2024-03-22 | 耶鲁大学 | 通过e3泛素连接酶增强靶蛋白质及其他多肽降解的化合物和方法 |
WO2015160845A2 (en) | 2014-04-14 | 2015-10-22 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
EP3256470B1 (en) * | 2014-12-23 | 2023-07-26 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
US9694084B2 (en) * | 2014-12-23 | 2017-07-04 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
AU2016209349B2 (en) * | 2015-01-20 | 2020-05-07 | Arvinas, Inc. | Compounds and methods for the targeted degradation of the Androgen Receptor |
MA41598A (fr) * | 2015-02-25 | 2018-01-02 | Constellation Pharmaceuticals Inc | Composés thérapeutiques de pyridazine et leurs utilisations |
CN108601764A (zh) | 2015-03-18 | 2018-09-28 | 阿尔维纳斯股份有限公司 | 用于靶蛋白的增强降解的化合物和方法 |
MX2018000360A (es) * | 2015-07-10 | 2018-06-11 | Arvinas Inc | Moduladores basados en mdm2 de proteolisis y metodos de uso asociados. |
AU2016294450A1 (en) * | 2015-07-13 | 2017-12-07 | Arvinas Operations, Inc. | Alanine-based modulators of proteolysis and associated methods of use |
WO2017030814A1 (en) | 2015-08-19 | 2017-02-23 | Arvinas, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
AU2016349781A1 (en) * | 2015-11-02 | 2018-05-10 | Yale University | Proteolysis targeting chimera compounds and methods of preparing and using same |
US20180215731A1 (en) | 2017-01-31 | 2018-08-02 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
CN107698657A (zh) * | 2017-09-26 | 2018-02-16 | 中国药科大学 | 基于vhl配体和bet抑制剂诱导bet降解的双功能分子及其制备和应用 |
-
2019
- 2019-04-01 CR CR20200527A patent/CR20200527A/es unknown
- 2019-04-01 PE PE2020001522A patent/PE20212108A1/es unknown
- 2019-04-01 JP JP2020553643A patent/JP2021520350A/ja active Pending
- 2019-04-01 MX MX2020010368A patent/MX2020010368A/es unknown
- 2019-04-01 KR KR1020247027581A patent/KR20240130153A/ko active Application Filing
- 2019-04-01 AU AU2019249849A patent/AU2019249849C1/en active Active
- 2019-04-01 US US16/372,345 patent/US20190300521A1/en not_active Abandoned
- 2019-04-01 WO PCT/US2019/025254 patent/WO2019195201A1/en active Application Filing
- 2019-04-01 CA CA3094305A patent/CA3094305A1/en active Pending
- 2019-04-01 EP EP19717685.2A patent/EP3774789A1/en active Pending
- 2019-04-01 BR BR112020020196-0A patent/BR112020020196A2/pt unknown
- 2019-04-01 KR KR1020207031366A patent/KR102697733B1/ko active IP Right Grant
- 2019-04-01 CN CN201980036295.9A patent/CN112166114A/zh active Pending
- 2019-04-01 SG SG11202008898UA patent/SG11202008898UA/en unknown
-
2020
- 2020-09-15 PH PH12020500663A patent/PH12020500663A1/en unknown
- 2020-09-30 IL IL277677A patent/IL277677A/en unknown
- 2020-10-01 MX MX2024000329A patent/MX2024000329A/es unknown
- 2020-10-01 CL CL2020002546A patent/CL2020002546A1/es unknown
- 2020-10-30 CO CONC2020/0013762A patent/CO2020013762A2/es unknown
-
2022
- 2022-06-10 AU AU2022204042A patent/AU2022204042A1/en not_active Abandoned
-
2023
- 2023-02-10 US US18/108,045 patent/US20240076295A1/en active Pending
- 2023-02-17 JP JP2023023039A patent/JP2023071767A/ja active Pending
-
2024
- 2024-05-08 AU AU2024203058A patent/AU2024203058A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
BR112020020196A2 (pt) | 2021-01-26 |
IL277677A (en) | 2020-11-30 |
EP3774789A1 (en) | 2021-02-17 |
SG11202008898UA (en) | 2020-10-29 |
US20240076295A1 (en) | 2024-03-07 |
WO2019195201A1 (en) | 2019-10-10 |
US20190300521A1 (en) | 2019-10-03 |
KR102697733B1 (ko) | 2024-08-26 |
JP2021520350A (ja) | 2021-08-19 |
AU2019249849B2 (en) | 2022-03-17 |
MX2020010368A (es) | 2021-01-08 |
PH12020500663A1 (en) | 2021-06-07 |
KR20240130153A (ko) | 2024-08-28 |
PE20212108A1 (es) | 2021-11-04 |
RU2020135754A (ru) | 2022-05-04 |
CO2020013762A2 (es) | 2021-01-18 |
CL2020002546A1 (es) | 2021-01-29 |
AU2024203058A1 (en) | 2024-05-30 |
KR20210005037A (ko) | 2021-01-13 |
RU2020135754A3 (es) | 2022-05-04 |
JP2023071767A (ja) | 2023-05-23 |
AU2019249849C1 (en) | 2022-09-29 |
CA3094305A1 (en) | 2019-10-10 |
CN112166114A (zh) | 2021-01-01 |
AU2019249849A1 (en) | 2020-10-01 |
CR20200527A (es) | 2021-04-09 |
AU2022204042A1 (en) | 2022-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2024000329A (es) | Compuestos bifuncionales que comprenden una molecula que contiene una porcion dirigida a la proteina smarca (ptm) enlazada a una porcion de una molecula de union de ligasa de ubiquitina e3 (ulm), y su uso como moduladores de la ubiquitinacion dirigidos al tratamiento del cancer. | |
MX2022014690A (es) | Protac dirigidos a la proteina tau y metodos asociados de uso. | |
MX2019008934A (es) | Moduladores de la proteolisis del receptor de estrogeno y métodos asociados de uso,. | |
MX2023010341A (es) | Moduladores de la proteolisis y metodos asociados de uso. | |
MX2022010583A (es) | Derivados de tetrahidronaftaleno y tetrahidroisoquinolina como degradores del receptor de estrogeno. | |
MX2022004526A (es) | Moléculas bifuncionales que contienen una porción de unión a la ligasa de ubiquitina e3 unida a una porción de direccionamiento a bcl6. | |
MX2023009031A (es) | Compuestos y metodos para la degradacion dirigida de polipeptidos de fibrosarcoma acelerado rapidamente. | |
MX2021002559A (es) | Compuestos policiclicos y metodos para la degradacion dirigida de polipeptidos de fibrosarcoma rapidamente acelerado. | |
WO2018119441A8 (en) | Egfr proteolysis targeting chimeric molecules and associated methods of use | |
MX2021010482A (es) | Compuestos y metodos para la degradacion mejorada de proteinas especificas. | |
PH12021500004A1 (en) | Pd-1/pd-l1 inhibitors | |
PH12020551244A1 (en) | Pd-1/pd-l1 inhibitors | |
MX2023008056A (es) | Ligandos de cereblon y compuestos bifuncionales que comprenden el mismo. | |
MX2017015605A (es) | Moduladores de proteolisis basados en imida y metodos de uso asociados. | |
MX2021012926A (es) | Moduladores de la proteolisis basados en imida y metodos de uso asociados. | |
JOP20220083A1 (ar) | حلقات غير متجانسة ثنائية الحلقة كمثبطات لـ fgfr | |
AU2018278311A1 (en) | IRE1 small molecule inhibitors | |
MX2018000360A (es) | Moduladores basados en mdm2 de proteolisis y metodos de uso asociados. | |
PH12017501483A1 (en) | Bicyclic heterocycles as fgfr4 inhibitors | |
MX2018000471A (es) | Moduladores de proteolisis basados en alanina y metodos de uso asociados. | |
WO2018026722A8 (en) | COMPOSITIONS AND METHODS FOR INHIBITING MASP-3 FOR THE TREATMENT OF VARIOUS DISEASES AND DISORDERS | |
MX2022006932A (es) | Combinaciones de inhibidores de diacilglicerol cinasas (dgk) y antagonistas de puntos de control. | |
CA3010678A1 (en) | Methods and compositions for enhancing the potency of superantigen mediated cancer immunotherapy | |
WO2019051327A3 (en) | BETA CATENIN FUNCTIONALIZATION AGENTS AND ASSOCIATED METHODS | |
EP4005569A3 (en) | Compositions for treating and/or preventing cell or tissue necrosis specifically targeting cathepsin c and/or cela1 and/or cela3a and/or structurally related enzymes thereto |